The cDNA encoding interferon-induced human double-stranded RNA-activated p68 kinase was expressed in murine NIH 3T3 cells by using the pcDNAl/neo vector. Several stable clones were selected which expressed either the wild-type kinase or an inactive mutant possessing a single amino acid substitution in the invariant lysine 296 in the catalytic domain II. The transfected wild-type kinase showed properties similar to those of the natural kinase, such as subcellular ribosomal localization and dependence on double-stranded RNA for autophosphorylation. Upon infection with encephalomyocarditis virus (EMCV), wild-type-but not mutantexpressing clones were found to partially resist virus growth. Such natural antiviral activity was virus specific, since no inhibition was observed in the case of vesicular stomatitis virus infection. In accord with EMCV inhibition, the wild-type p68 kinase was found to be highly phosphorylated during infection. Furthermore, its natural substrate, the small subunit of protein synthesis initiation factor eIF2, was phosphorylated. These results demonstrate that p68 kinase is activated during EMCV infection, leading to reduced virus production.
The interferon-induced, double-stranded RNA (dsRNA)-activated kinase is a cellular protein which has been implicated as one of the mechanisms responsible for inhibition of protein synthesis (through phosphorylation of the protein synthesis initiation factor eIF2). It is referred to as a p68 kinase in human cells and a p65 kinase in murine cells on the basis of Mr (15, 16) . The p68 and p65 kinases have been extensively characterized by biochemical studies and recently cloned (10, 29) . The dsRNA-activated protein kinase is a serine/threonine kinase that manifests two distinct kinase activities, one for autophosphorylation and the other for phosphorylation of its substrate. Activation requires binding of the protein to dsRNA molecules or, alternatively, to single-stranded RNA molecules presenting internal dsRNA structures (12, 13) . The regulatory region interacting with dsRNA has been localized toward the middle of the N-terminal region of the protein (10, 21) . Once phosphorylated, the p68 kinase is no longer dependent on its activator and phosphorylates its only known physiological substrate, the a subunit of eIF2. This effect has been shown by in vitro studies (11, 12) and in vivo experiments using cells previously treated with interferon to induce the dsRNA-activated kinase and then virus infected to provide for dsRNA activators (32, 37) . The function of eIF2a is to allow the formation of the initiation ternary complex eIF2-GTP-Met-tRNA and the subsequent binding of Met-tRNA to the 40S subunit of the ribosomes. When eIF2 completes one round of initiation, it is ejected from the ribosomes as eIF2-GDP, which can be recycled into the active eIF2-GTP complex, a reaction catalyzed by the guanine nucleotide exchange factor eIF2B.
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Phosphorylated eIF2a inhibits the function of eIF2B by sequestering it and stops any further initiation step (14) .
The dsRNA-activated human and murine protein kinases have a strong degree of sequence identity (38%) with the yeast GCN2 kinase in their catalytic kinase subdomains (4, 10) . Recombinant p68 kinase has recently been expressed in the yeast Saccharomyces cerevisiae and shown to exhibit a growth-suppressive phenotype which could be attributed to its own activation in yeast cells and the subsequent phosphorylation of the SUI gene product, the equivalent in yeast cells of the mammalian eIF2a (4, 5) . These results reveal the capacity of p68 kinase to mediate inhibition protein synthesis through phosphorylation of eIF2oa. Although the yeast system provides an excellent genetic approach to an understanding of the dsRNA-activated kinase function in vivo, the exact role of this kinase in its natural environment, i.e., mammalian cells, remained to be demonstrated, as does its role in the mechanism of the antiviral action of interferon. Here we report the establishment of mammalian clones constitutively expressing the human p68 kinase and present direct evidence for selective reduction of encephalomyocarditis virus (EMCV) growth in these clones concomitantly with in vivo phosphorylation of eIF2a.
MATERIALS AND METHODS
Reagents. [.y-32P]ATP, [35S] methionine, and 1251I-labeled goat anti-mouse immunoglobulins were supplied by Amersham. Poly(I)-poly(C), heparin, and cycloheximide (CHX) were from Sigma. Mouse interferon (cytimmune mouse x/I interferon; 5 (29) . The cDNA was then excised by HindIII-BamHI digestion and inserted into the HindIII-BamHI-cut pcDNA1/neo eucaryotic expression vector (Invitrogen). The Lys-296--Pro-296 and Lys-296--+Arg-296 mutants were generated by sitespecific mutagenesis as described elsewhere (21) .
Transfection. Murine NIH 3T3 cells were plated in 60-mmdiameter dishes at 104 cells per dish and used after 24 h. The culture medium was replaced with fresh medium, and after 3 h at 37°C, 10 ,ug of pcDNAl/neo vector carrying the wildtype or each mutant p68 kinase was precipitated on the cells by the calcium phosphate coprecipitation technique. After 4 h of incubation, the cells were subjected to a glycerol shock for 2 min, washed once with complete medium, and cultivated for 2 days. Cells were trypsinized and plated in 25-cm2 flasks in medium containing G418 at a concentration of 200 ,ug/ml for the first 2 days and then at 400 ,ug/ml. On day 11, the surviving cells were collected by trypsinization and cloned in 24-well plates in growth medium containing 20% serum and 400 ,ug of G418 per ml. On day 21, isolated clones were trypsinized and grown for further study. Each transfection gave a yield of 10 to 20 drug-resistant clones.
Virus assay. The cells were plated at 2 x 105 cells per well in 24-well plates. After 36 h, they were washed once with phosphate-buffered saline (PBS) and incubated for 60 min at 37°C with 0.4 ml of PBS containing EMCV or VSV at the multiplicity of infection (MOI) required. The virus-containing medium was removed, and the cells were further incubated in 10% serum-containing medium. At 10 to 12 h after infection, the plates were frozen and thawed twice, and the virus supernatants were collected and centrifuged at 2,500 rpm to eliminate debris. The virus yields from each clone were titered on HeLa cells plated on six-well plates at 3 x 105 cells per well and used after 3 days. The virus (dilutions 10-2 to 10-7 in PBS) was adsorbed onto the cells for 60 min, the virus-containing medium was removed, and the cells were covered with Dulbecco's modified Eagle's medium containing 0.5% serum and 0.6% agarose (Indubiose A37 HAA; IBF, Villeneuve-la-Garenne, France). After 3 days of incubation at 37°C, the cells were fixed in 5% trichloroacetic acid for 30 min at 4°C, the agarose-containing medium was removed under water, and the plaques were visualized by staining with a solution of 0.1% crystal violet in 20% ethanol.
Assay of the dsRNA-dependent protein kinase. Cell extracts corresponding to 1.5 x 106 cells were incubated with 20 ,ul of MAb-Sepharose in 0.5 ml of buffer A for a minimum of 3 h at 4°C. MAb-Sepharose-bound kinase samples were washed batchwise first in buffer A and then in buffer B before incubation (15 
RESULTS
Isolation of murine clones expressing the human p68 kinase. Murine cells were used in this study since the molecular masses of the human (68 kDa) and murine (65 kDa) dsRNAactivated protein kinases allow discrimination between the endogenous and the transfected kinases. NIH 3T3 cells were transfected with the expression vector pcDNA1/neo carrying cDNA expressing the p68 kinase either as wild type (active kinase) or mutated by a single amino acid substitution to proline or to arginine at the invariant lysine 296 (21) . It has previously been shown for a number of other protein tyrosine or serine/threonine kinases that the Lys residue of the catalytic subdomain II is involved in the phosphate transfer reaction and that a single-point mutation involving this amino acid completely inhibits kinase activity (for references, see reference 31). After selection in G418-containing medium, we obtained approximately 10 4. (24) by amplifying expression of the transfected kinase in response to treatment of cells with CHX and the synthetic dsRNA poly(I)-poly(C). Both reagents have been reported to induce the expression of several genes, including the ,3-interferon gene, through NF-KB activation (9, 25, 33, 40) . Three weeks after transfection and subcloning, neomycinresistant clones were plated (3 x 105 cells) in duplicate. One culture was retained, and the other was incubated in presence of CHX and poly(I)-poly(C) under conditions described for the induction of dsRNA-responsive genes (40) . Cells were labeled in [35S]methionine-containing medium, and the kinase was analyzed by immunoprecipitation with a specific MAb and subsequent gel electrophoresis. In these experiments, we used monoclonal instead of polyclonal antibodies since the latter are known to cross-react with the murine p65 kinase (29) and thus might give false-positive results in our assay. Clones positive for the presence of the p68 kinase are presented in Fig. 1 . Poly(I)-poly(C)/CHX treatment resulted in the increased expression of the transfected p68 kinase, while in the absence of such treatment, kinase levels were barely detectable. This procedure allowed us to generate a series of independent clones expressing either the wild-type p68 kinase (clones 68.10, 68.11.1, and 1718.9) or the Lys--Pro (clones 13.2 and 13.5) or Lys-*Arg (clones 12 Fig. 2A show that the wild-type and the mutant p68 kinases are constitutively expressed in clones 68.11.1 and 12.3, respectively. Treatment of both clones with murine interferon did not affect expression of the transfected kinase but did induce the murine endogenous p65 kinase to levels comparable to those induced in the Neo clone alone. The capacity to induce the murine p65 kinase following interferon treatment indicates that our cloning procedure did not affect the ability of the cells to respond to interferon. Both p65 and p68 kinases were detected in the same blot by using polyclonal antibodies raised against the human p68 kinase which cross-react with the murine kinase (29) . The cDNA for the murine p65 kinase has recently been cloned and sequenced, revealing a high level of sequence homology with the human kinase (71% overall homology when conservative changes were taken into account [10] ). Besides the murine p65 kinase, anti-p68 kinase polyclonal antibodies cross-react with a 80-kDa protein which is constitutively expressed in these murine cells ( Fig. 2A) The clones expressing the pcDNAl/neo vector alone (Neo), the wild-type p68 kinase (68.11.1; wt), or the p68 kinase carrying the Lys-296--'Arg-296 mutation (12.3; lys-arg) were grown in the absence (-) or presence (+) of 500 U of mouse a/,B interferon per ml for 18 h, and the cell extracts were prepared as described previously (13) . Extracts corresponding to 1.3 x 106 cells were separated by PAGE (8.5% polyacrylamide gel) and analyzed by immunoblotting with polyclonal antibodies specific for human p68 kinase (29) and anti-mouse immunoglobulin antibodies coupled to horseradish peroxidase (ECL; Amersham). (B) Association of the transfected p68 kinase with the postribosomal fraction. Clones Neo (lanes 1 and 2) and 68.11.1 (lanes 3 and 4) were lysed in homogenization low-salt buffer, and mitochondrial (lanes 1 and 3) and microsomal (lanes 2 and 4) pellets were prepared (Materials and Methods). Equivalent aliquots corresponding to 1.5 x 106 cells were separated by PAGE (8.5% polyacrylamide gel) and assayed by immunoblotting (29) with polyclonal antibodies specific for the human p68 kinase and '1I-labeled goat anti-mouse immunoglobulins (Amersham). An autoradiograph is shown. (C) Functional expression by the transfected kinase. MAb-Sepharose-purified p68 kinase (corresponding to 1.5 x 106 cells) was prepared from clone 68.11.1 (wild-type kinase) and from clone 12.3 (Arg-296 mutant kinase). The enzyme was assayed for autophosphorylation in the presence of different concentrations of poly(I)-poly(C) (IC; 0, 0.01, 0.1, and 1 ,ug/ml) or 10 U of heparin per ml (lanes H) as described in Materials and Methods (17) . Extracts from interferon-treated Daudi cells (1.3 x 106 cells) were included in the assay as controls. The samples were analyzed by SDS-PAGE (8.5% gel). An autoradiograph is shown. Sizes are indicated in kilodaltons.
polyclonal antibodies raised against urea-denatured 69-kDa 2',5'-oligoadenylate (2-5A) synthetase (not shown) (16) .
Subcellular fractionation studies in Daudi (12) and HeLa (8) cells have previously shown that the natural human p68 kinase is associated with the microsomal pellet, i.e., the 100,000 x g pellet also containing ribosomes. Results in Fig.  2B show that the human p68 kinase expressed in clone 68.11.1 was also found to be associated with the ribosomal pellet. In these experiments, the endogenous p65 kinase was not clearly detectable since control cells (not interferon treated) were used.
The p68 kinase from the wild-type and the Arg-296 mutant clones were assayed for protein kinase activity in vitro (Fig.  2C) . The transfected wild-type kinase manifested p68 kinase activity, as demonstrated by autophosphorylation in the presence of heparin or poly(I)-poly(C). In the latter case, autophosphorylation is dependent on the concentration of poly(I)-poly(C) and is one of the major properties of the p68 kinase (12) . A similar pattern of activation was observed for the transfected wild-type kinase and for the natural p68 kinase (Fig. 2C) . As expected, the Arg-296 mutant manifested no p68 kinase activity. a The cells were infected with EMCV or VSV at an MOI of 0.1 PFU per cell, and the virus yields from each clone were titered on HeLa cells (Materials and Methods). Virus yields from two independent experiments are presented. In experiment 2, some of the virus yields were titered in duplicate. In experiment 3, the cells were first untreated (EMCV) or treated with 500 U of interferon per ml before EMCV infection (IFN + EMCV). ND, not determined.
Thus, the human p68 kinase can be expressed constitutively in murine NIH 3T3 cells with properties (in vitro autophosphorylation and subcellular localization) identical to those of the natural kinase expressed in human cells.
Inhibition of EMCV growth in clones expressing the human p68 kinase. We then assessed whether clones expressing the wild-type p68 kinase (68.11.1, 1718.9, and 68.10) could resist viral infection in comparison with the control Neo clone and clones expressing the mutant kinase (12.3 and 13.5). Clones were infected with EMCV at a low MOI (0.1), and after 10 h of infection (one cycle = 7 to 8 h), plates were frozen and thawed and virus yields were plaque assayed. Growth of the virus was found to be consistently lower in wild-type kinaseexpressing clones than in the control Neo clone or clones expressing the mutant inactive kinase. The degree of inhibition of EMCV yield in wild-type kinase-expressing cells was variable from one experiment to the other. Table 1 gives the results of three typical experiments that illustrate the degree of minimal (0.94-log-unit) and maximal (2.1-log-unit) inhibition observed. Our results therefore show that constitutive expression of the p68 kinase can produce significant resistance to EMCV growth (90 to 99% inhibition). This antiviral state, however, remains lower than a fully antiviral state established after interferon treatment. This effect was monitored by interferon treatment prior to EMCV infection in some representative clones which showed a maximum antiviral response corresponding to 1.8-to 3.2-log-unit inhibition (Table 1 , experiment 3). It is interesting to note that in the interferon-treated clones, EMCV yields were reduced 0.6 to 1.8 log units more in the wild-type than in the Neo or mutant kinase clones. Since the kinase-expressing clones showed about a log reduction in virus yields without interferon treatment, this increased inhibition in EMCV yields probably reflects additive antiviral actions between the constitutively expressed kinase and other antiviral events induced by interferon in these clones (including the induced endogenous murine kinase). It may also be possible that the transfected kinase contributes to transcriptional activation of interferonrelated genes involved in antiviral action. Taken together, the significant reduction of EMCV yields in wild-typeexpressing clones compared with those expressing the mutant inactive kinase clearly implicates the function of the p68 kinase in an antiviral action against EMCV.
Resistance of kinase-expressing clones to EMCV growth was also found to be MOI dependent (Fig. 3) . As the MOI increased from 0.1 to 1 or 5, the wild-type-expressing clones showed decreased resistance to the virus whereas clone Neo and two clones expressing the inactive kinase supported virus growth at comparable levels for each MOI. These data suggest that clones expressing the wild-type kinase are less resistant to EMCV infection when many viral particles are involved. This situation is similar to the effect of increasing MOI on the antiviral activity of interferon. However, it should be noted that for each MOI used in the experiments described here, the virus yields obtained from the wild-typeexpressing clones remained lower than the yields obtained from the controls. This result again argues in favor of constitutive EMCV resistance in the wild-type kinase-expressing clones.
The purified p68 kinase has been shown to be activated in vitro by low concentrations of dsRNA, whereas high concentrations of dsRNA render the kinase inactive (13) . In view of this finding, it is possible that the decreased anti-EMCV resistance in the wild-type-expressing clones is due to inactivation of the wild-type p68 kinase by high concentrations of dsRNA-like structures that accumulate at high MOI.
VSV growth is not inhibited in clones expressing the wildtype kinase. The growth of VSV was not inhibited in any of the clones expressing the wild-type kinase compared with Neo or mutant kinase-expressing clones (Table 1) . Similar distinctions between the two viruses (reduction of EMCV but not of VSV yields) were also reported for clones constitutively expressing the small 2-5A synthetase (3, 6 against VSV is mediated by mechanisms distinct from the 2-5A synthetase or kinase pathway.
The in vivo state of phosphorylation of the transfected p68 kinase. EMCV growth was reduced in clones expressing the wild-type p68 kinase but not in clones expressing a mutant p68 kinase. This finding suggested that the expression of a functional kinase was required for the inhibition of virus growth. For this reason, we analyzed the in vivo autophosphorylation state of the p68 kinase and its ability to phosphorylate its natural substrate, eIF2. In these experiments, we used polyclonal antibodies specific for the p68 kinase and the a subunit of eIF2 to monitor by immunoblotting the phosphorylated and unphosphorylated species of each protein after resolution by 2D gel analysis (Fig. 4 and 5 Following 2D gel analysis, the p68 kinase was revealed as several related species with similar isoelectric points in the range of 8.2 to 7.8 (22) . These species represent unphosphorylated and some slightly phosphorylated p68 kinase molecules. Because of their capacity to be phosphorylated at several sites, highly phosphorylated p68 kinase molecules became resolved as highly acidic species (22, 23) . We therefore used a shift toward the acidic pH value as a reference for the phosphorylated state of the wild-type and mutant p68 kinases with or without infection by EMCV (Fig.  4) . In the absence of virus infection, the wild-type and mutant p68 kinases were expressed predominantly as unphosphorylated species. In addition, a minor phosphorylated form, which represents 10% of the total protein, can be observed in the pattern of the wild-type kinase (Fig. 4) . Analysis of extracts prepared at 6 h postinfection with EMCV (a time when most of the virus was under active replication) revealed differences in the phosphorylation patterns of the wild-type and mutant kinase; the wild-type p68 kinase from infected cells migrated as a highly phosphorylated subspecies as expected from in vivo activation through the viral dsRNA replicative intermediates. In addition, we observed a significant decrease in the physical levels of the kinase. On the other hand, the Arg-296 mutant kinase showed only a partially phosphorylated pattern, and its level remained unchanged. Phosphorylation of the mutant kinase was not surprising since although the Lys--Arg substitution abrogates the kinase function, it leaves intact the ability of the protein to be phosphorylated at its serine and threonine residues.
We have previously observed loss of the human p68 kinase upon EMCV infection. This effect, which was attributed to trapping of the kinase in cellular compartments, not accessible to Triton X-100 extraction (8, 15) . However, the mutant kinase was not lost during EMCV infection, suggesting that EMCV-mediated trapping of the kinase to membrane compartments may require activation of the kinase. The dramatic shift toward the acidic pH value indicates that the wild-type kinase is highly phosphorylated during EMCV infection.
In vivo phosphorylation of eIF2 in clones expressing the wild-type kinase upon EMCV infection. The wild-type p68 kinase (in clone 68.11.1) can be activated in vivo as it becomes highly phosphorylated upon infection with EMCV (Fig. 4) . Therefore, we next analyzed the ability of this transfected p68 kinase to phosphorylate eIF2 during EMCV infection. The acidic (phosphorylated) and basic (unphosphorylated) subspecies of eIF2 were separated on isoelectric focusing gels. We expected that in clone 68.11.1, which expressed the wild-type p68 kinase, eIF2 would become phosphorylated during EMCV infection regardless of interferon treatment, whereas clone 12.3, which expressed an inactive kinase, should behave as the Neo clone does. In these latter two clones, eIF2 may become phosphorylated in interferon-treated and virus-infected cells as a result of the induction and activation of the endogenous murine p65 kinase. The results (Fig. 5) show that this is indeed the case. In EMCV-infected clone 68.11.1, eIF2 was resolved as two subspecies, one basic (60%) and one acidic (40%), representing the unphosphorylated and phosphorylated forms, respectively (Fig. 5) . However, in EMCV-infected clone 12.3, eIF2 was resolved only as a major basic unphosphorylated species. When clone 68.11.1 was first treated with interferon and then infected, the percentage of phosphorylated eIF2 increased to 50% of the total eIF2. Such additional phosphorylation may be attributed to the endogenous murine p65 kinase, which is induced by interferon (Fig. IA) and becomes activated along with the constitutive wild-type p68 kinase. In EMCV-infected clone 12.3, eIF2 was phosphorylated only after interferon treatment, similarly to the Neo clone and as a result of interferon induction of the endogenous mouse p65 kinase and its subsequent activation during EMCV infection.
DISCUSSION
We have constitutively expressed the human dsRNAdependent p68 kinase in murine NIH 3T3 cells under the control of the cytomegalovirus promoter. Transfection of the p68 kinase cDNA either as wild type or as a catalytic subdomain II mutant cDNA allowed the generation of several clones expressing either a functional kinase or its inactive homolog.
The transfected p68 kinase was found to be associated with the ribosomal fraction, as described for the natural human p68 kinase (8, 12) . Moreover, it possessed the same dependence on activation by dsRNA or heparin as did the natural p68 kinase (17) . Therefore, we can assume that the transfected recombinant human p68 kinase expressed in NIH 3T3 clones has retained the intrinsic properties of its natural human counterpart. Since this enzyme is expressed in the absence of other interferon-induced gene products, NIH 3T3 clones therefore provided a useful system with which to determine the role of the p68 kinase in the mechanism of the antiviral action of interferon.
Clones expressing the wild-type but not the mutant kinase (3, 6, 36) . Taken together, these observations indicate that the two interferon-induced dsRNA-activated enzymes, the p68 kinase and the 2-5A synthetase, restrict their antiviral action to certain viruses. This effect is probably a consequence of the replication cycle of each virus.
The primary site of the antiviral action of interferon on EMCV is at the translational level, whereas that on VSV may occur at the level of primary transcription (1, 27) or/and viral protein synthesis (39) . Virus maturation may also be affected (26, 38) . A differential antiviral response was also reported in interferon-treated HeLa cells, in which the p68 kinase was shown to be reduced during a heat shock stress; cells remained antiviral for VSV but not for EMCV (7) . Thus, loss of the p68 kinase was associated with loss of anti-EMCV resistance. In clones expressing the wild-type kinase, the resistance to EMCV was at a lower efficiency than in clones expressing the 2-5A synthetase (3, 6, 36) . This difference is most probably due to amplification of the action of 2-5A by synthesis of 2'-5'-linked oligoadenylates which then activate a latent endoribonuclease responsible for degradation of RNA (16 (13, 19, 28) . Poliovirus infection induces p68 kinase degradation (2) . Human immunodeficiency virus type 1 downregulates the p68 kinase through the action of the viral protein Tat (34, 35) . Influenza virus blocks the kinase activity by activating a cellular inhibitor of the kinase (20) . More (4) . It is possible that the degree of activity of the p68 kinase on eIF2 depends on its serine/ threonine phosphorylation ratio. It has been reported previously that the phosphorylated serine/threonine ratio changes after interferon treatment (22) . This may also be the case during EMCV infection and in yeast cells. It 
